Oligodendroglioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 16: | Line 16: | ||
===Chemotherapy=== | ===Chemotherapy=== | ||
*[[Chemotherapy]] is indicated as adjuvant therapy for oligodendroglioma<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref><ref name="pmid9776413">{{cite journal| author=Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al.| title=Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. | journal=J Natl Cancer Inst | year= 1998 | volume= 90 | issue= 19 | pages= 1473-9 | pmid=9776413 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9776413 }} </ref> | *[[Chemotherapy]] is indicated as adjuvant therapy for oligodendroglioma<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref><ref name="pmid9776413">{{cite journal| author=Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al.| title=Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. | journal=J Natl Cancer Inst | year= 1998 | volume= 90 | issue= 19 | pages= 1473-9 | pmid=9776413 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9776413 }} </ref><ref name="pmid23071247">{{cite journal| author=Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al.| title=Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 3 | pages= 337-43 | pmid=23071247 | doi=10.1200/JCO.2012.43.2674 | pmc=3732012 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23071247 }} </ref> | ||
*Oligodendroglioma responds better to chemotherapy than astrocytoma of comparable grade<ref name="pmiddoi:10.1016/S0090-3019(03)00167-8">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/S0090-3019(03)00167-8 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | *Oligodendroglioma responds better to chemotherapy than astrocytoma of comparable grade<ref name="pmiddoi:10.1016/S0090-3019(03)00167-8">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/S0090-3019(03)00167-8 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | ||
*Oligodendroglioma is the most chemosensitive of all the [[glioma|glial tumors]]<ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171 }} </ref> | *Oligodendroglioma is the most chemosensitive of all the [[glioma|glial tumors]]<ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171 }} </ref> | ||
Revision as of 14:10, 9 May 2019
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma medical therapy |
|
Risk calculators and risk factors for Oligodendroglioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
The predominant therapy for oligodendroglioma is surgical resection. Adjunctive chemotherapy and radiation are required. Supportive therapy for oligodendroglioma includes anticonvulsants and corticosteroids.
Medical Therapy
The medical therapy of oligodendroglioma includes:
Radiotherapy
- Post-operative radiotherapy is recommended among all patients who develop oligodendroglioma[1][2]
- Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival
- External beam radiation therapy is preferred to whole brain radiotherapy[1]
- External beam radiation therapy is usually administered in standard fractions of 1.8–2 Gy and can reach a total dose of 60 Gy[3]
Chemotherapy
- Chemotherapy is indicated as adjuvant therapy for oligodendroglioma[1][4][5]
- Oligodendroglioma responds better to chemotherapy than astrocytoma of comparable grade[6]
- Oligodendroglioma is the most chemosensitive of all the glial tumors[7]
- Symptomatic, aggressive, enlarging, enhancing, and non-anaplastic oligodendrogliomas respond better to chemotherapy[8]
- Temozolomide (Temodar) is the preferred drug for the treatment of oligodendroglioma[1]
- PCV 3 regimen is the preferred combination chemotherapy for anaplastic oligodendroglioma[1][9]
- CCNU is administered on day 1, procarbazine is administered daily for 14 days beginning on day 8, and vincristine is administered on days 8 and 29 of each 6-week cycle of therapy[10]
- Other chemotherapeutic drugs that may be used for the treatment of oligodendroglioma include:[11][7]
- If oligodendroglioma is unresponsive to the chemotherapeutic drugs used in earlier treatments or if it recurs, other drugs that may be used include:[11]
Supportive treatment
- Supportive therapy for oligodendroglioma includes anticonvulsants and corticosteroids, which focuses on relieving symptoms and improving the patient’s neurologic function[1]
- Anticonvulsants are administered to the patients who have a seizure
- Phenytoin given concurrently with radiation may have serious skin reactions such as erythema multiforme and Stevens-Johnson syndrome.
- Corticosteroids, usually dexamethasone given 4-10 mg every 4-6 h, can reduce peritumoral edema, diminish mass effect, and lower intracranial pressure with a decrease in symptoms (headache or drowsiness)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on
- ↑ Harat M, Blok M, Harat A, Soszyńska K (2019). "The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas". Onco Targets Ther. 12: 2215–2224. doi:10.2147/OTT.S200818. PMC 6441459. PMID 30988626.
- ↑ Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
- ↑ Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR; et al. (1998). "Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas". J Natl Cancer Inst. 90 (19): 1473–9. PMID 9776413.
- ↑ Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J; et al. (2013). "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402". J Clin Oncol. 31 (3): 337–43. doi:10.1200/JCO.2012.43.2674. PMC 3732012. PMID 23071247.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/S0090-3019(03)00167-8 Check
|pmid=value (help). - ↑ 7.0 7.1 Cairncross JG, Macdonald DR (1988). "Successful chemotherapy for recurrent malignant oligodendroglioma". Ann Neurol. 23 (4): 360–4. doi:10.1002/ana.410230408. PMID 3382171.
- ↑ Cairncross JG, Macdonald DR, Ramsay DA (1992). "Aggressive oligodendroglioma: a chemosensitive tumor". Neurosurgery. 31 (1): 78–82. PMID 1641113.
- ↑ Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). "Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets". Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
- ↑ Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
- ↑ 11.0 11.1 Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on